Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

695 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients.
Besarab A, Chernyavskaya E, Motylev I, Shutov E, Kumbar LM, Gurevich K, Chan DT, Leong R, Poole L, Zhong M, Saikali KG, Franco M, Hemmerich S, Yu KH, Neff TB. Besarab A, et al. Among authors: yu kh. J Am Soc Nephrol. 2016 Apr;27(4):1225-33. doi: 10.1681/ASN.2015030241. Epub 2015 Oct 22. J Am Soc Nephrol. 2016. PMID: 26494833 Free PMC article. Clinical Trial.
Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.
Provenzano R, Besarab A, Wright S, Dua S, Zeig S, Nguyen P, Poole L, Saikali KG, Saha G, Hemmerich S, Szczech L, Yu KH, Neff TB. Provenzano R, et al. Among authors: yu kh. Am J Kidney Dis. 2016 Jun;67(6):912-24. doi: 10.1053/j.ajkd.2015.12.020. Epub 2016 Feb 2. Am J Kidney Dis. 2016. PMID: 26846333 Free article. Clinical Trial.
Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.
Besarab A, Provenzano R, Hertel J, Zabaneh R, Klaus SJ, Lee T, Leong R, Hemmerich S, Yu KH, Neff TB. Besarab A, et al. Among authors: yu kh. Nephrol Dial Transplant. 2015 Oct;30(10):1665-73. doi: 10.1093/ndt/gfv302. Epub 2015 Aug 3. Nephrol Dial Transplant. 2015. PMID: 26238121 Free PMC article. Clinical Trial.
Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD.
Provenzano R, Besarab A, Sun CH, Diamond SA, Durham JH, Cangiano JL, Aiello JR, Novak JE, Lee T, Leong R, Roberts BK, Saikali KG, Hemmerich S, Szczech LA, Yu KP, Neff TB. Provenzano R, et al. Clin J Am Soc Nephrol. 2016 Jun 6;11(6):982-991. doi: 10.2215/CJN.06890615. Epub 2016 Apr 19. Clin J Am Soc Nephrol. 2016. PMID: 27094610 Free PMC article. Clinical Trial.
Adjuvant Modified FOLFIRINOX for Resected Pancreatic Adenocarcinoma (PDAC): Clinical Insights and Genomic Features from a Large Contemporary Cohort.
Keane F, O'Connor C, Moss D, Chou JF, Perry MA, Crowley F, Saxena P, Chan A, Schoenfeld JD, Singhal A, Park W, Cowzer D, Harrold E, Varghese AM, El Dika I, Crane C, Harding JJ, Abou-Alfa GK, Kingham TP, Wei AC, Yu KH, D'Angelica MI, Balachandran VP, Drebin J, Jarnagin WR, Bandlamudi C, Kelsen D, Capanu M, Soares KC, Balogun F, O'Reilly EM. Keane F, et al. Among authors: yu kh. J Natl Cancer Inst. 2024 Oct 26:djae269. doi: 10.1093/jnci/djae269. Online ahead of print. J Natl Cancer Inst. 2024. PMID: 39460946
Impact of non-traditional lipid profiles on 1-year vascular outcomes in ischemic stroke patients with prior statin therapy and LDL-C < 100 mg/dL.
Kim H, Kim JT, Lee JS, Kim BJ, Kang J, Lee KJ, Park JM, Kang K, Lee SJ, Kim JG, Cha JK, Kim DH, Park TH, Lee K, Lee J, Hong KS, Cho YJ, Park HK, Lee BC, Yu KH, Oh MS, Kim DE, Choi JC, Kwon JH, Kim WJ, Shin DI, Yum KS, Sohn SI, Hong JH, Lee SH, Park MS, Ryu WS, Park KY, Lee J, Saver JL, Bae HJ. Kim H, et al. Among authors: yu kh. Sci Rep. 2024 Oct 1;14(1):22794. doi: 10.1038/s41598-024-73851-5. Sci Rep. 2024. PMID: 39354143 Free PMC article.
Effects of white matter hyperintensity burden on functional outcome after mild versus moderate-to-severe ischemic stroke.
Gwak DS, Ryu WS, Schellingerhout D, Chung J, Kim HR, Jeong SW, Kim BJ, Kim JT, Hong KS, Park JM, Park MS, Choi KH, Park TH, Lee K, Park SS, Kang K, Cho YJ, Park HK, Lee BC, Yu KH, Oh MS, Lee SJ, Kim JG, Cha JK, Kim DH, Lee J, Han MK, Lee JS, Bae HJ, Kim DE. Gwak DS, et al. Among authors: yu kh. Sci Rep. 2024 Sep 29;14(1):22567. doi: 10.1038/s41598-024-71936-9. Sci Rep. 2024. PMID: 39343768 Free PMC article.
Medical Artificial Intelligence and Human Values. Reply.
Manrai AK, Yu KH, Kohane IS. Manrai AK, et al. Among authors: yu kh. N Engl J Med. 2024 Sep 26;391(12):1167-1168. doi: 10.1056/NEJMc2408971. N Engl J Med. 2024. PMID: 39321381 No abstract available.
695 results